Anosognosia and the Criminalization of Schizophrenia: Implications for Clinical Practice

Meet “Jared,” a man in his late twenties with schizophrenia who is living in the community. He has been prescribed an antipsychotic by his local community mental health center but stopped taking it months ago. Since he “knows” he does not suffer from a mental illness, Jared misses multiple appointments and his clinic closes his case. He is homeless, using various street drugs, and floridly psychotic.

After a series of arrests, Jared commits a felony: murder. While in jail, he is eventually found Incompetent to Stand Trial and is then transferred to a state hospital for competency restoration, after a long delay. Jared returns to the jail with his trial competency restored, where he decompensates again before his hearing.

At some point, he is likely to be adjudicated Not Guilty by Reason of Insanity, going on to spend years in the forensic hospital system. Or he may be found Guilty and sent into the prison system instead. Either way, he winds up functioning better under the umbrella of the criminal justice system, because it provides a higher, policy-driven level of structure and supervision than the civil system. Family members of loved ones in forensic hospitals find themselves asking: Why did my son have to kill someone to get care like this?

This is a composite drawn from decades of work in jails, prisons, and forensic state hospitals across multiple states. This is not 1 person; It is a pattern largely driven by a specific neurological symptom.

Anosognosia

Anosognosia is a neurological deficit—one of some 20 to 30 recognized agnosias—in which an affected individual is unable to perceive their own illness. It is well established in stroke, traumatic brain injury, and dementia.

And it is remarkably prevalent in schizophrenia. The WHO International Pilot Study of Schizophrenia, spanning 9 countries and over 1200 patients, identified poor insight as the single most common symptom of the illness—more prevalent than hallucinations, delusions, or flat affect. Among the "concordant group" of 306 patients whose diagnoses were independently confirmed by both local clinicians and the standardized CATEGO classification system, 97% demonstrated lack of insight.¹ Amador et al, using the first validated insight rating tool in a multi-site study of 412 patients, found that 57% of those with schizophrenia had moderate to severe unawareness of their mental disorder.²

Does treatment fix this? Not reliably. A meta-analysis of 14 randomized controlled trials found that second-generation antipsychotics improved insight scores by only 0.28 points more than placebo on a 7-point scale.³ Adding psychotherapy or psychoeducation to medication produced small or nonsignificant additional gains.⁴ And in a study tracking first-episode patients over 2 years of assured long-acting injectable treatment, self-rated illness awareness did not significantly improve—even as clinician-rated insight did, suggesting that clinicians may conflate cooperation with comprehension.⁵

Most psychiatrists are familiar with anosognosia in principle. However, the operational outcome of this agnosia is not obvious because so many of those who are afflicted are “out of sight, out of mind,” invisibly homeless on the street, incarcerated, or admitted to a forensic hospital.

This is the clinical reality that confronts the community psychiatrist, the assertive community treatment (ACT) team, the crisis clinician. An individual with schizophrenia and anosognosia has a reduced capacity to participate in informed consent. They are neurologically unable to recognize the need for treatment, yet our civil mental health system is built on informed consent and patient autonomy—a framework that presumes the very capacity their illness has taken from them.

The Pipeline: From Civil Failure to Forensic Custody

Consider the sequence. An individual with anosognosic schizophrenia stops medication. They miss appointments. The outpatient clinic, bound by consent-based service models, drops them from the caseload. They deteriorate. Substance use is frequent and worsens the illness. Eventually there is a crisis—a law enforcement encounter. If the officer diverts them to a crisis unit, they may spend a few days there before discharge, resume nonadherence, and cycle back. If the encounter involves an offense, they enter the criminal justice system, where lengths of stay are much longer, and supervision, structure, and accountability are higher.

The numbers tell us where this pipeline terminates. An estimated 77,000 individuals with psychotic disorders are in American jails and prisons at any given time—roughly 2.7 times the approximately 29,000 in state psychiatric hospitals, more than half of whose beds are now occupied by forensic patients.^6,7 Another 108,000 individuals with psychotic disorders are homeless.⁸ State psychiatric bed capacity has declined 96% per capita since 1955—from 340 beds per 100,000 to 10.8.⁷

The civil system’s response to treatment refusal in this population is, functionally, to wait. ACT community teams pursue engagement vigorously but have no legal authority to compel treatment. Assisted outpatient treatment (AOT) civil court programs are sometimes available, and mandate participation. However, associated AOT statutes are not written to allow compelled medication administration outside a hospital. When a patient in an AOT program refuses stabilizing medication, the available response is a court hearing (“black robe effect”) and potential hospitalization. Medication can be compelled during civil state hospitalizations, however that authority ends as patients walk out the door.

The forensic system, by contrast, responds to treatment refusal not with abandonment but with continued custody and legal process. In prisons, an administrative hearing under Washington v Harper (1990) can authorize involuntary medication with no judge involved. In forensic hospitals, Sell v United States (2003) provides a pathway for compelled medication to restore trial competency. For hospitalized patients deemed Not Guilty by Reason of Insanity, compelled medications can accompany annual commitments.

Evidence for Treatment With Antipsychotics

The evidence for antipsychotic treatment in reducing the very outcomes this pipeline produces is substantial. In a nationwide Finnish study with 20-year follow-up, clozapine and long-acting injectables cut rehospitalization roughly in half.⁹ Discontinuation of antipsychotics after 5 or more years of stable use was associated with a 7-fold increase in risk of rehospitalization or death.¹⁰ Among previously incarcerated patients with schizophrenia in the PRIDE trial, roughly 1 in 5 on a monthly injectable were rearrested, compared with nearly 1 in 3 on daily oral medication.¹¹

A Swedish national study of nearly 75,000 patients found a 47% reduction in violent crime arrests and a 33% reduction in any-crime arrests during periods on antipsychotic medication compared with periods off it.¹² Adherence below 80% was associated with 41% to 58% higher rates of violent offending in a Canadian cohort of over 11,000 offenders with schizophrenia.¹³

These findings are not subtle. Medication adherence materially reduces hospitalization, incarceration, violence, and death. And the single greatest driver of nonadherence in schizophrenia is the neurological symptom that prevents the patient from knowing they need the medication in the first place.

The Autonomy Paradox

The civil mental health system treats treatment refusal as an exercise of autonomy. This makes sense for patients who have functional levels of illness insight. They can adequately weigh the risks and benefits of various treatments. But what about the patient whose illness has destroyed their capacity to recognize that they are ill? When we honor that refusal as a “right,” what exactly are we protecting?

This is not an abstract philosophical question. It has a body count, a jail census, and a growing backlog of defendants found incompetent to stand trial who wait months to years in county jails for forensic hospital beds that do not exist. These are people too psychotic to understand court proceedings, warehoused in jails (Washington v Harper does not apply to pre-adjudication inmates) without adequate treatment while the civil system that might have intervened earlier observes helplessly from the sidelines.

For patients with anosognosia, the civil system’s respect for autonomy can function as a mechanism of abandonment. We say: “We offered services. They declined.”

Implications for Clinical Practice

Outpatient and community psychiatrists encounter anosognosia frequently, even if they do not always name it thus: The patient with a severe mental illness who “just won’t take their meds,” the one who “disappeared from services,” the one the family calls about in desperation while the clinic says there is nothing they can do. These are not simply failures of motivation. These are often the result of a neurological deficit as concrete as the hemiplegia denial seen in right-hemisphere stroke patients.

Recognizing anosognosia for what it is—a neurological symptom, not a preference—does not by itself solve structural problems. The civil system is built to require hospitalization to compel medication, and workers within the system know how difficult it can be to access those services. But if clinicians cannot yet change the legal framework, they can at least stop mistaking a neurological deficit for patient choice. That shift in understanding is a precondition for every policy reform that might follow broader use of assisted outpatient treatment, capacity-based rather than dangerousness-based commitment standards, and the expansion of long-acting injectable prescribing as a frontline strategy for patients with known adherence deficits.

The question that haunts forensic psychiatry—the one asked by the family in the case vignette—is not really about why their son received good care in a state hospital, but about why good care required a felony as the admission ticket. The answer, in an uncomfortable number of cases, begins with a neurological symptom we have known about for decades and still have not built a system to address.

Dr Hager is a board-certified psychiatrist and clinical informaticist. He serves as medical advisor and board member for the National Shattering Silence Coalition. He has over 2 decades of practice worked across jails, prisons, forensic state hospitals, jail-based competency restoration programs, and community mental health settings in Florida, Indiana, and Texas.

References

1. Sartorius N, Shapiro R, Jablensky A. The international pilot study of schizophrenia. Schizophr Bull. 1974;1(11):21-34.

2. Amador XF, Flaum M, Andreasen NC, et al. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry. 1994;51(10):826-836.

3. Mattila T, Koeter M, Wohlfarth T, et al. The impact of second generation antipsychotics on insight in schizophrenia: results from 14 randomized, placebo controlled trials. Eur Neuropsychopharmacol. 2017;27(1):82-86.

4. Phelan S, Sigala N. The effect of treatment on insight in psychotic disorders—a systematic review and meta-analysis. Schizophr Res. 2022;244:126-133.

5. Phahladira L, Asmal L, Kilian S, et al. Changes in insight over the first 24 months of treatment in schizophrenia spectrum disorders. Schizophr Res. 2019;206:394-399.

6. Emilian F, Al-Juffali N, Fazel S. Prevalence of severe mental illness among people in prison across 43 countries: a systematic review and meta-analysis. Lancet Public Health. 2025;10(2):e97-e110.

7. Silver S, Hancq ES. Prevention over punishment: finding the right balance of civil and forensic state psychiatric hospital beds. Treatment Advocacy Center. January 2024. Accessed May 4, 2026. https://www.tac.org/reports_publications/state-psychiatric-hospital-beds/

8. Barry R, Anderson J, Tran L, et al. Prevalence of mental health disorders among individuals experiencing homelessness: a systematic review and meta-analysis. JAMA Psychiatry. 2024;81(7):691-699.

9. Taipale H, Mehtälä J, Tanskanen A, Tiihonen J. Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia—a nationwide study with 20-year follow-up. Schizophr Bull. 2018;44(6):1381-1387.

10. Tiihonen J, Tanskanen A, Taipale H. 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry. 2018;175(8):765-773.

11. Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board–blinded 15-month study (PRIDE). J Clin Psychiatry. 2015;76(5):554-561.

12. Sariaslan A, Leucht S, Zetterqvist J, et al. Associations between individual antipsychotics and the risk of arrests and convictions of violent and other crime: a nationwide within-individual study of 74,925 persons. Psychol Med. 2022;52(16):3792-3800.

13. Rezansoff SN, Moniruzzaman A, Fazel S, et al. Adherence to antipsychotic medication and criminal recidivism in a Canadian provincial offender population. Schizophr Bull. 2017;43(5):1002-1010.